T0	Outcomes 368 488	LCS6 genotype and its association with KRAS mutation status, clinicopathologic features, and disease-free survival (DFS)
T1	Outcomes 815 832	and KRAS mutation
T2	Outcomes 1023 1044	(15.2%) blood samples
T3	Outcomes 1053 1123	(14.6%) tumor samples heterozygous or homozygous for the LCS6 G-allele
T4	Outcomes 1181 1236	(85.4%) tumor samples homozygous for the LCS6 T-allele.
T5	Outcomes 1237 1253	Genotype results
T6	Outcomes 1338 1339	.
T7	Outcomes 1340 1357	G-allele carriers
T8	Outcomes 1449 1466	The LCS6 genotype
T9	Outcomes 1486 1539	with KRAS mutation status, clinicopathologic features
T10	Outcomes 1555 1561	or DFS
T11	Outcomes 1665 1690	with KRAS mutation status